Important note: Information in this article was accurate in May 2004. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - Vol. 5, No. 6, July 2004
This issue includes reports from the recent resistance meeting in Tenerife – in which we include reviews of the research with the relevance to clinical practice – and Gareth Hardy provides an overview of the highly specialised Keystone meeting that took place in April.
We also round up some of the recent developments in international access to treatment. In the meantime, alarms were raised following the announcement on May 27th that the WHO had removed two Cipla products from its prequalification list: 3TC, manufactured as Lamivir and the AZT/3TC fixed dose combination, manufactured as Duovir, due to concerns over a bioequivalence study.
Although a gift to many detractors of generic antiretrovirals, a spokeswomen from MSF explained: “The fact that there is ongoing monitoring of drugs on the prequalification list by the WHO should be seen as a sign of an efficient process”, Cipla must submit new data and we should expect a result by the end of July.
Our next double issue will be August/September and will cover the World AIDS Conference taking place in Bangkok from 11-16 July. The programme for this meeting is now online at:
HIV Treatment Bulletin
HTB is a monthly journal published in print and electronic format by HIV i-Base. As with all i-Base publications, subscriptions are free and can be ordered directly from the i-Base website:
by sending an email to:
or by fax or post using the form on the back page.
Editorial Staff
Editor in Chief: Paul Blanchard
Editor: Simon Collins
Associate Editor: Graham McKerrow
Commissioning Editor: Polly Clayden
Medical Consultants:
Dr Sanjay Bhagani, Royal Free Hospital, London.
Dr Karen Beckerman, Bellevue Hospital, New York.
Dr Gareth Hardy, Royal Free Hospital, London.
Dr Saye Khoo, University of Liverpool Hospital.
Prof. Clive Loveday, International Laboratory Virology Centre.
Dr Graeme Moyle, Chelsea & Westminster Hosp, London.
Dr Stefan Mauss, Düsseldorf.
Dr Stephen Taylor, Birmingham Heartlands Hospital.
Dr Gareth Tudor-Williams, Imperial College, London.
HTB is a not-for-profit community publication that aims to provide a review of the most important medical advances related to clinical management of HIV and its related conditions as well as access to treatments. Comments to articles are compiled from consultant, author and editorial responses.
Some articles are reproduced from other respected sources and copyright for these articles remains with the original authors and sources, as indicated at the end of each article.
We thank those organisations for recognising the importance of providing widely distributed free access to information both to people living with HIV and to the healthcare professionals involved in their care. We also thank them for permission to distribute their excellent work and we encourage HTB readers to visit the source websites for further access to their coverage of HIV treatment.
Articles written and credited to i-Base writers, as with all i-Base originated material, remains the copyright of HIV i-Base, but these articles may be reproduced by community and not-for-profit organisations without individual written permission and reproduction is encouraged. A credit and link to the original author, the HTB issue and the i-Base website is always appreciated.
HIV i-Base receives unconditional educational grants from Charitable Trusts, individual donors and pharmaceutical companies.All editorial policies are strictly independent of funding sources.
HIV i-Base
Third Floor East, Thrale House
44-46 Southwark Street, London SE1 1UN
T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
HIV i-Base is a registered charity no 1081905 and company reg no 3962064.
HTB is also known as DrFax
040710
IB040506-01
©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
